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ABSTRACT
Primary bone tumors and cancers that metastasize to bone require osteoclastic activity to release
tumor-supportive growth factors from bone tissue. A number of systemic and locally acting factors are
known to influence osteoclast formation, fusion, activation, and survival. Recently, two critical extracel-
lular regulators of osteoclast differentiation and activation have been identified: receptor activator of
nuclear factor (NF-kappaB) ligand (RANKL) and osteoprotegerin (OPG). RANKL is a tumor necrosis fac-
tor (TNF)-related cytokine that stimulates osteoclast differentiation from hematopoietic precursor cells
and activation of mature osteoclasts. RANKL activates its specific receptor, receptor activator of NF-
kappaB (RANK), located on osteoclasts, chondrocytes and dendritic cells. Binding of the RANK ligand to
its receptor and osteoclastogenesis are prevented by osteoprotegerin, a decoy receptor produced by
osteoblasts and marrow stromal cells. The balance between RANKL and OPG is of major importance in
bone homeostasis. Disorders of the RANKL/RANK/OPG system have been linked to several human dis-
eases, including primary bone tumors, skeletal metastases, and hypercalcemia of malignancy. The dis-
covery and characterization of RANKL, RANK and OPG and subsequent studies have changed the con-
cepts of bone metabolism and may form the basis of innovative therapeutic strategies. Novel treatment
strategies for bone tumors are emerging based on blockade of the RANKL/RANK interaction. The advan-
tage of these strategies is their potential to selectively target tumor cells. Combining these new strate-
gies with currently available treatments such as chemotherapy and radiation therapy is under investiga-
tion, with promising results.
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INTRODUCTION 
B
one is a highly hospitable environment for colonization and growth of metastatic tumors
(1). Some of the most common human malignancies, notably breast cancer and
prostate cancer, have a strong propensity to produce skeletal metastases (2,3). Over 70%
of patients with advanced breast or prostate cancer have skeletal metastases (2). Beside
secondary tumors, primary tumors such as osteosarcoma and giant-cell tumors can also
arise in bone.  In order for tumor cells to grow and invade mineralized bone, osteolysis must
occur (4,5). Mineralized bone matrix is a rich source of stored growth factors such as trans-
forming growth factor-b (TGF-b), insulin-like growth factors (IGFs) and fibroblast growth
factor-2 (FGF-2) (6). Such growth factors, once released from degraded bone matrix, may
further accelerate growth of the tumor, which can now expand within the lysed area (4). 
The cells responsible for the resorption of bone tissue are the osteoclasts. This cell type is
of hematopoietic origin and differentiates in a late phase from the monocyte/macrophage
cell lineage to form a giant, multinucleated cell that can attach to mineralized bone tissue
(7). An increase in osteolysis is thus usually associated with an increase in the number or
the activity of bone-resorbing osteoclasts. A number of systemic and locally acting factors
are known to influence osteoclast formation, activation, lifespan, and function (8). These
include parathyroid hormone (PTH) (9), PTH-related protein, corticosteroids (10),
prostaglandin E2 (11), hepatocyte growth factor - HGF (12), macrophage inflammatory pro-
tein (MIP)-1a and MIP-1b (13), tumor necrosis factor-a (TNF-a) and TNF-b (14), vitamin
D, bone morphogenetic protein-2 (15), interleukin-1 (IL-1), IL-6, IL-11 (16). The formation
of active osteoclasts requires macrophage colony-stimulating factor (M-CSF) and involves
cell-to-cell contact between precursors of the monocyte-macrophage lineage and
osteoblasts, marrow stromal cells, and T and B cells (17). Recently, an essential cytokine
system for osteoclast biology has been characterized (18,19). This system consists of a
ligand, receptor activator of NF-kappaB ligand (RANKL), a cellular receptor, RANK, and a
soluble decoy receptor, osteoprotegerin (OPG) (20). Since the discovery of this trio of TNF
family proteins, it was fond that nearly all osteotrophic hormones and local pro-resorptive
factors produced in the bone microenvironment mediate their action indirectly via
RANKL/OPG expression (21).
THE RANKL/RANK/OPG SYSTEM
RANKL is a specific and essential differentiation factor for osteoclast precursors and anessential activation factor for mature osteoclasts. Synonyms for RANKL are OPG ligand,
osteoclast differentiation factor (ODF), and TNF-related activation-induced cytokine
(TRANCE) (22). The rankl gene encodes a TNF superfamily molecule of 316 amino acids,
and three RANKL subunits assemble to form the functional trimeric molecule (22). Trimeric
RANKL is made as a membrane anchored molecule, but it can be released from the cell sur-
face as a soluble homotrimeric molecules after proteolytic cleavage by the metalloprotease
disintegrin TNF-a convertase (TACE) (23). Both soluble and membrane bound RANKL can
function as potent agonistic ligands for osteoclastogenesis in vitro, but membrane bound
RANKL might work more efficiently than soluble RANKL (24). RANKL is extensively
expressed by osteoblast/stromal cells (25), primitive mesenchymal cells, chondrocytes,
immune and some cancer cells (26). The specific cellular receptor that transduces the
actions of RANKL was named RANK. RANK is a member of TNF-R superfamily; it is
expressed on the surface of hematopoietic osteoclasts progenitors, mature osteoclasts,
chondrocytes, mammary gland epithelial cells and dendritic cells (27). The binding of
RANKL to RANK plays an important role in promoting osteoclast differentiation and bone
resorption (28). Mice with a genetic mutation of RANK display severe osteopetrosis, ces-
sation of growth, and a defect in tooth eruption (29). Osteoprotegerin (OPG, "protector of
bone"), as the name implies, protects bone by potent inhibition of osteoclast activation. It
was identified in 1997 by two distinct lines of investigation (30). Synonyms for OPG are
osteoclastogenesis-inhibitory factor (OCIF) and TNFR-related molecule 1 (31).
Osteoprotegerin is a 401-amino acid secreted glycoprotein with homology to members of
the TNF receptor family (27). In contrast to all other TNFR superfamily members, OPG lacks
transmembrane and cytoplasmic domains and it is secreted as a soluble protein (17). OPG
is produced ubiquitously by many types of cells, and it has very high expression level in the
bone marrow microenvironment (32). This glycoprotein acts as a non-signaling decoy
receptor for RANKL. Consequently, OPG is an effective inhibitor of osteoclast maturation
and activation (24). Mice with overexpression of OPG have decreased osteoclast formation
and develop osteopetrosis, whereas mice deficient in OPG have reduced bone mass and
develop osteoporosis (33). 
The balance between RANKL and OPG is of major importance in bone homeostasis (34).
Abnormalities of the RANKL-to-OPG ratio have been implicated in the pathogenesis of post-
menopausal osteoporosis, rheumatoid arthritis, periodontal disease, benign and malignant
bone tumors, bone metastases, and hypercalcemia of malignancy (35).
THE RANKL-TO-OPG RATIO IN BONE TUMORS 
Extensive in vitro and animal studies have detected abnormalities of the RANKL:OPG ratio
in various benign and malignant neoplasms characterized by abnormal osteoclast function
(35). The RANKL:OPG ratio was significantly increased in patients suffering from breast
cancer, giant-cell tumors and multiple myeloma (35). Breast cancer cells can secrete PTH-
related protein which increases RANKL and decreases OPG expression by osteoblasts,
resulting in enhanced osteoclastogenesis and bone resorption with creating cavities in bone
where tumor cells are able to expand (36). Giant-cell tumors consist of a stromal cell pop-
ulation of the osteoblastic lineage that overexpresses RANKL, and they also contain large
osteoclasts-like "giant cells" that are hyperresponsive to RANKL (37). Together, these
effects result in increased osteoclast activity. Myeloma cells increase RANKL expression
and inhibit OPG production within the bone microenvironment (38). Furthermore, myeloma
cells can bind, internalize, and degrade OPG (34). 
Opposite to osteolytic bone tumors, prostate carcinoma skeletal metastases and osteosar-
coma often grow as osteoblastic tumors. In these patients high OPG levels have been
detected and the RANKL:OPG ratio have been significantly decreased (21). These findings
indicate that the RANKL:OPG ratio may affect tumor growth by inhibiting osteoclast activi-
ty to allow increased osteoblast proliferation (21). However, some animal studies have been
shown that OPG inhibits prostate cancer-induced osteoclastogenesis and prevents prostate
tumor growth in the bone (5). These data suggest that inhibition of osteoclast activity is suf-
ficient to diminish the development of skeletal metastatic prostate tumors that have both
osteolytic and osteoblastic components.         
UTILIZATION OF THE OPG/RANKL SYSTEM IN THERAPY
It was shown in several studies that in animal disease models administering of OPG could
restore the RANKL/OPG imbalance. Beside OPG, a recombinant OPG fusion protein (OPG-
Fc) or inhibitory RANK antibodies (RANK-Fc) have been used. RANK-Fc is a recombinant
RANKL antagonist that is formed by fusing the extracellular domain of RANK to the Fc por-
tion of human immunoglobulin G1 (IgG1) (39). Treatment of animals with OPG-Fc or RANK-
Fc appears to be effective in conditions associated with upregulated bone resorption (40).
Administration of OPG prevents ovariectomy-induced osteoporosis, establishment and pro-
gression of osteolytic metastasis, skeletal pain and humoral hypercalcemia of malignancy
(35). OPG is currently in phase I clinical trials. In 2001 Bekker et al. tested the effect of OPG
in postmenopausal women. In this study, biochemical markers of bone turnover rapidly
decreased after a single subcutaneous injection of OPG (41). More recently, a similar
approach has been used in patients with myeloma bone disease. In this study, patients
receiving 1 mg/kg of OPG-Fc displayed a rapid, sustained decrease of the biochemical
marker of bone resorption (42). The results of mentioned experiments suggest that OPG
might represent an effective therapeutic option for diseases associated with excessive
osteoclast activity (41). 
CONCLUSION
RANKL, its receptor RANK, and the decoy receptor OPG are the key regulators for osteo-
clast development and the activation of mature osteoclasts. The balance of RANKL and OPG
determines osteoclast activity (bone resorption). The RANKL:OPG ratio was significantly
increased in patients suffering from severe osteolysis. It has become clear that inhibition of
RANKL mediated activation of RANK via OPG or a related molecules (recombinant OPG pro-
tein or RANK-Fc) may be an effective anabolic treatment for reduced bone mass, manage-
ment of cancer-induced bone pain, prevention of the development of skeletal metastases,
and hypercalcemia of malignancy. The advantage of these therapeutic strategies is their
potential to selectively target tumor cells, while exempt normal cells. Combining these new
strategies with currently available treatments such as chemotherapy and radiation therapy
is under investigation, with promising results.
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